Showing results (341-350 of 413) with videos related to
Sort By:
Pageof 42
Cancer Cell|August 17, 2013
Amplification of distant estrogen response elements deregulates target genes associated with tamoxifen resistance in breast cancerPei-Yin Hsu, Hang-Kai Hsu, Xun Lan, et al.Disease Markers|July 20, 2004
Serum protein expression profiling for cancer detection: validation of a SELDI-based approach for prostate cancerWilliam E Grizzle, Bao-Ling L Adam, William L Bigbee, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2015
SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate CancerEvan Y Yu, Hongli Li, Celestia S Higano, et al.The Prostate|March 21, 2017
Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention TrialDanyelle A Winchester, Cathee Till, Phyllis J Goodman, et al.JNCI Cancer Spectrum|May 6, 2020
Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With DocetaxelSusan Halabi, Sandipan Dutta, Catherine M Tangen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 5, 2020
17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) CohortDaniel W Lin, Yingye Zheng, Jesse K McKenney, et al.The Journal of Urology|October 26, 2019
African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance StudyJeannette M Schenk, Lisa F Newcomb, Yingye Zheng, et al.The New England Journal of Medicine|November 26, 2024
Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder CancerSeth P Lerner, Catherine Tangen, Robert S Svatek, et al.International Journal of Cancer|September 16, 2014
Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trialAmir Goldkorn, Benjamin Ely, Catherine M Tangen, et al.The Prostate|January 16, 2016
Key genes involved in the immune response are generally not associated with intraprostatic inflammation in men without a prostate cancer diagnosis: Results from the prostate cancer prevention trialDanyelle A Winchester, Bora Gurel, Cathee Till, et al.Pageof 42